Sodium oxybate

(Xyrem®)

Sodium oxybate

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormSolution (oral; 0.5 g/ml)
Drug ClassCentral nervous system depressants
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Sodium oxybate (Xyrem) is indicated for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy.
  • Four studies were reviewed, focusing on the safety and effectiveness of sodium oxybate compared to other pharmacological interventions for narcolepsy.
  • In terms of effectiveness, solriamfetol was found to be superior to sodium oxybate in improving excessive daytime sleepiness. However, sodium oxybate showed wide-ranging efficacy in improving a variety of narcolepsy-related symptoms including cataplexy attacks and subjective daytime sleepiness.
  • Regarding safety, while effective, sodium oxybate presents less favorable tolerability due to dose-dependent side effects. High doses and recurrent use may lead to potential risks such as possible neurotoxicity leading to cognitive impairments.
  • Compared with solriamfetol, which shows superior efficacy but might not offer a better efficacy-safety balance than sodium oxybate; pitolisant and modafinil are suggested as options based on individual health profiles and potential side effects.
  • The studies underscored the importance of tailored treatment approaches considering variations in responses between drugs. Detailed subgroup analyses were not provided, indicating that these findings apply broadly across the general narcolepsy patient population without delving into specific subgroups.